Insulin resistance, obesity and hypertension: Is the link waist circumference?

Therapy

Volumn 4, Issue 5, 2007, Pages 575-583

  Chateau Degat, Marie Ludivine ^a   Poirier, Paul ^b  

^a LAVAL UNIVERSITY   (Canada)

^b LAVAL UNIVERSITY   (Canada)

Author keywords

Adipokines; Cardiovascular diseases; Hypertension; Insulin resistance; Obesity; Physiopathology; Waist circumference

Indexed keywords

ANGIOTENSIN II; ANGIOTENSINOGEN; INSULIN;

ABDOMINAL OBESITY; ADRENERGIC SYSTEM; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLINERGIC SYSTEM; DISEASE ASSOCIATION; ESSENTIAL HYPERTENSION; HUMAN; HYPERINSULINEMIA; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PATHOPHYSIOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SUBCUTANEOUS FAT; WAIST CIRCUMFERENCE;

EID: 35348872632     PISSN: 14750708     EISSN: 1744831X     Source Type: Journal    
DOI: 10.2217/14750708.4.5.575     Document Type: Review

References (92)

1. Zimmet P, Magliano D, Matsuzawa Y, Alberti G, Shaw J: The metabolic syndrome a global public health problem and a new definition. J Atherosler. Thromb. 12(6), 295-300 (2005).
2. Welborn TA, Breckenridge A, Rubinstein AH, Dollery CT, Fraser TR: Serum-insulin in essential hypertension and in peripheral vascular disease. Lancet 1 (7451), 1336-1337 (1966).
3. Reaven GM, Lithell H, Landsberg L: Hypertension and associated metabolic abnormalities the role of insulin resistance and the sympathoadrenal system. N. Engl. J. Med. 334(6), 374-381 (1996).
4. Saad MF, Rewers M, Selby J et al.: Insulin resistance and hypertension: the Insulin Resistance Atherosclerosis Study. Hypertension 43(6), 1324-1331 (2004).
5. Lin MW, Hwu CM, Huang YH et al.: Directly measured insulin resistance and the assessment of clustered cardiovascular risks in hypertension. Am. J. Hypertens. 19(11), 1118-1124 (2006).
6. Denker PS, Pollock VE: Fasting serum Insulin levels in essential hypertension. A meta-analysis. Arch. Intern. Med. 152(8), 1649-1651 (1992).
7. Haffner SM, Miettinen H, Gaskill SP, Stern MP: Metabolic precursors of hypertension. The San Antonio Heart Study. Arch. Intern. Med. 156(17), 1994-2001 (1996).
8. Liese AD, Mayer-Davis EJ, Chambless LE et al.: Elevated fasting insulin predicts incident hypertension: the ARIC study. Atherosclerosis Risk in Communities Study Investigators. J. Hypertens. 17(8), 1169-1177 (1999).
9. Dyer AR, Liu K, Walsh M et al.: Ten-year incidence of elevated blood pressure and its predictors: the CARDIA study. Coronary Artery Risk Development in (Young) Adults. J. Hum. Hypertens. 13(1). 13-21 (1999).
10. Salonen JT, Lakka TA, Lakka HM et al.: Hyperinsulinemia is associated with the incidence of hypertension and dyslipidemia in middle-aged men. Diabetes 47(2), 270-275 (1998).
11. Goff DC Jr, Zaccaro DJ. Haffner SM, Saad MF: Insulin sensitivity and the risk of incident hypertension: insights from the Insulin Resistance Atherosclerosis Study. Diabetes Care 26(3), 805-809 (2003).
12. Ferrannini E, Natali A, Capaldo B et al.: Insulin resistance, hyperinsulinemia and blood pressure: role of age and obesity. European Group for the Study of Insulin Resistance (EGIR). Hypertension 30(5), 1144-1149 (1997).
13. Falkner B, Sherif K, Sumner AE. Kushner H: Blood pressure increase with impaired glucose tolerance in young adult american blacks. Hypertension 34(5), 1086-1090 (1999).
14. Tseng CH: Exogenous insulin use and hypertension In adult patients with Type 2 diabetes mellitus. Arch. Intern. Med. 166(11), 1184-1189 (2006).
15. Shimamoto K, Ura N: Mechanisms of Insulin resistance in hypertensive rats. Clin. Exp. Hypertens. 28(6), 543-552 (2006).
16. Hill AB: The environment and disease: association or causation? Proc. R. Soc. Med. 58, 295-300 (1965).
17. Brands MW Hall JE. Keen HL: Is insulin resistance linked to hypertension? Clin. Exp. Pharmacol. Physiol. 25(1), 70-76 (1998).
18. Sawicki PT. Heinemann L, Starke A. Berger M: Hyperinsulinaemia is not linked with blood pressure elevation in patients with insulinoma. Diabetologia 35(7), 649-652 (1992).
19. Vettor R, Mazzonetto P, Macor C, Scandellari C, Federspil G: Effect of endogenous organic hyperinsulinaemia on blood pressure and serum triglycerides. Eur. J. Clin. Invest. 24(5), 350-354 (1994).
20. Golden SH, Wang NY, Klag MJ, Meoni LA, Brancati FL: Blood pressure in young adulthood and the risk of Type 2 diabetes in middle age. Diabetes Care 26(4), 1110-1115 (2003).
21. Rheaume C, Waib PH, Kouame N et al.: Effects of intense and prolonged exercise on insulin sensitivity and glycogen metabolism in hypertensive subjects. Circulation 108(21), 2653-3659 (2003).
22. Bianchi S. Bigazzi R, Quinones Galvan A et al.: Insulin resistance In microalbuminuric hypertension. Sites and mechanisms. Hypertension 26(5), 789-795 (1995).
23. Natali A, Taddei S, Quinones Galvan A et al.: Insulin sensitivity, vascular reactivity and clamp-induced vasodilatation in essential hypertension. Circulation 96(3), 849-855 (1997).
24. Baron AD, Brechtel-Hook G, Johnson A, Hardin D: Skeletal muscle blood flow. A possible link between Insulin resistance and blood pressure. Hypertension 21(2). 129-135 (1993).
25. Hulthen UL, Endre T, Mattiasson I. Berglund G: Insulin and forearm vasodilation in hypertension-prone men. Hypertension 25(2), 214-218 (1995).
26. Bloomgarden ZT: Second World Congress on the Insulin Resistance Syndrome: hypertension, cardiovascular disease and treatment approaches. Diabetes Care 28(8), 2073-2080 (2005).
27. Sharma AM, Chetty VT: Obesity, hypertension and insulin resistance. Acta Diabetol. 42(Suppl. 1), S3-S8 (2005).
28. Zeng G. Quon MJ: Insulin-stimulated production of nitric oxide is inhibited by wortmannin. Direct measurement in vascular endothelial cells. J. Clin. Invest. 98(4), 894-898 (1996).
29. Kopp W: Pathogenesis and etiology of essential hypertension: role of dietary carbohydrate. Med. Hypotheses 64(4), 782-787 (2005).
30. Muller DC, Elahi D, Pratley RE, Tobin JD, Andres R: An epidemiological test of the hyperinsulinemia-hypertension hypothesis. J. Clin. Endocrinol. Metab. 76(3), 544-548 (1993).
31. Rocchini AP: Insulin resistance, obesity and hypertension. J. Nutr. 125(6 suppl.) 1718S-1724S (1995).
32. Blair D. Habicht JP, Sims EA, Sylwester D, Abraham S: Evidence for an increased risk for hypertension with centrally located body fat and the effect of race and sex on this risk. Am. J. Epidemiol. 119(4), 526-540 (1984).
33. Modan M, Halkin H, Fuchs Z et al.: Hyperinsulinemia - a link between glucose intolerance, obesity, hypertension, dyslipoproteinemia, elevated serum uric acid and internal cation imbalance. Diabete Metab. 13(3 Pt 2), 375-380 (1987).
34. Hu G, Qiao Q, Tuomilehto J et al.: Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch. Intern. Med. 164(10), 1066-1076 (2004).
35. Perticone F, Ceravolo R, Candigliota M et al.: Obesity and body fat distribution induce endothelial dysfunction by oxidative stress: protective effect of vitamin C. Diabetes 50(1), 159-165 (2001).
36. Yvan-Charvet L, Even P, Bloch-Faure M et al.: Deletion of the angiotensin type 2 receptor (AT2R) reduces adipose cell size and protects from diet-induced obesity and insulin resistance. Diabetes 54(4), 991-999 (2005).
37. Mukasa K: Antihypertensive drugs and insulin resistance in obesity. Intern. Med. 44(5), 395-396 (2005).
38. Da Silva AA, Kuo JJ, Taliam, LS, Liu J, Hall JE: Does obesity induce resistance to the long-term cardiovascular and metabolic actions of melanocortin 3/4 receptor activation? Hypertension 47(2), 259-264 (2006).
39. de Jongh RT, Ijzerman RG, Serne EH et al.: Visceral and truncal subcutaneous adipose tissue are associated with impaired capillary recruitment in healthy individuals. J. Clin. Endocrinol. Metab. 91(12), 5100-5106 (2006).
40. Poirier P, Hernandez TL, Well KM, Shepard TJ, Eckel RH: Impact of diet-induced weight loss on the cardiac autonomic nervous system in severe obesity. Obes. Res. 11(9), 1040-1047 (2003).
41. Poirier P, Eckel RH: Obesity and cardiovascular disease. Curr. Atheroscler. Rep. 4(6), 448-453 (2002).
42. Paul M, Wagner J, Dzau VJ: Gene expression of the renin-angiotensin system in human tissues. Quantitative analysis by the polymerase chain reaction. J. Clin. Invest. 91(5), 2058-2064 (1993).
43. Karisson C, Lindell K, Ottosson M et al.: Human adipose tissue expresses angiotensinogen and enzymes required for its conversion to angiotensin II. J. Clin. Endocrinol. Metab. 83(11): 3925-3929 (1998).
44. Masuzaki H, Yamamoto H, Kenyon CJ et al.: Transgenic amplification of glucocorticoid action in adipose tissue causes high blood pressure in mice. J. Clin. Invest. 112(1), 83-90 (2003).
45. Massiera F, Bloch-Faure M. Ceiler D et al.: Adipose angiotensinogen is involved in adipose tissue growth and blood pressure regulation. Faseb. J. 15(14), 2727-2729 (2001).
46. Giacchetti G, Faloia E, Sardu C et al.: Gene expression of angiotensinogen in adipose tissue of obese patients. Int. J. Obes. Relat. Metab. Disord. 24(Suppl. 2), S142-S143 (2000).
47. Engeli S, Gorzelniak K. Kreutz R et al.: Co-expression of renin-angiotensin system genes in human adipose tissue. J. Hypertens. 17(4), 555-560 (1999).
48. Crandall DL, Armellino DC, Busler DE, McHendry-Rinde B, Kral JG: Angiotensin II receptors in human preadipocytes: role in cell cycle regulation. Endocrinology 140(1), 154-159 (1999).
49. Ikeda T, Gomi T, Hirawa N. Sakurai J, Yoshikawa N: Improvement of insulin sensitivity contributes to blood pressure reduction after weight loss in hypertensive subjects with obesity. Hypertension 27(5), 1180-1186 (1996).
50. Muscelli E, Emdin M. Natali A et al.: Autonomic and hemodynamic responses to insulin in lean and obese humans. J. Clin. Endocrinol. Metab. 83 (6), 2084-2090 (1998).
51. Carmelli D. Cardon LR, Fabsitz R: Clustering of hypertension, diabetes, and obesity in adult male twins: same genes or same environments? Am. J. Hum. Genet. 55(3). 566-573 (1994).
52. Sharma AM: Mediastinal fat, insulin resistance, and hypertension. Hypertension 44(2), 117-118 (2004).
53. Dalton M, Cameron AJ, Zimmet PZ et al.: Waist circumference, waist-hip ratio and body mass index and their correlation with cardiovascular disease risk factors in Australian adults. J. Intern. Med. 254(6), 555-563 (2003).
54. Yusuf S, Hawken S, Ounpuu S et al.: Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 366(9497), 1640-1649 (2005).
55. Ferreira I, Snijder MB, Twisk JW et al.: Central fat mass versus peripheral fat and lean mass: opposite (adverse versus favorable) associations with arterial stiffness? The Amsterdam Growth and Health Longitudinal Study. J. Clin. Endocrinol. Metab. 89(6), 2632-2639 (2004).
56. Vague J: Dietetics in arterial hypertension. Mars. Med. 108(11), 781-783 (1971).
57. Krotkiewski M, Bjorntorp P, Sjostrom L, Smith U: Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution. J. Clin. Invest. 72(3), 1150-1162 (1983).
58. Nisoli E, Carruba MO, Tonello C et al.: Induction of fatty acid translocase/CD36, peroxisome proliferator-activated receptor-γ2, leptin, uncoupling proteins 2 and 3, and tumor necrosis factor-α gene expression in human subcutaneous fat by lipid infusion. Diabetes 49(3), 319-324 (2000).
59. Bjorntorp P, Holm G, Rosmond R, Folkow B: Hypertension and the metabolic syndrome: closely related central origin? Blood Press. 9(2-3), 71-82 (2000).
60. Poirier P, Giles TD, Bray GA et al.: Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 113(6), 898-918 (2006).
61. Giacchetti G, Faloia E, Mariniello B et al.: Overexpression of the renin-angiotensin system in human visceral adipose tissue in normal and overweight subjects. Am. J. Hypertens. 15(5), 381-388 (2002).
62. Aubert J, Darimont C, Safonova I, Ailhaud G. Negrel R: Regulation by glucocorticoids of angiotensinogen gene expression and secretion in adipose cells. Biochem. J. 328 (Pt 2), 701-706 (1997).
63. Bjorntorp P: Do stress reactions cause abdominal obesity and comorbidities? Obes. Rev. 2(2), 73-86 (2001).
64. Umemura S, Nyui N, Tamura K et al.: Plasma angiotensinogen concentrations in obese patients. Am. J. Hypertens. 10(6), 629-633 (1997).
65. van Harmelen V, Elizalde M, Ariapart P et al.: The association of human adipose angiotensinogen gene expression with abdominal fat distribution in obesity. Int. J. Obes. Relat. Metab. Disord. 24(6), 673-678 (2000).
66. Egan BM, Hennes MM, Stepniakowski KT et al.: Obesity hypertension is related more to insulin's fatty acid than glucose action. Hypertension 27(3 Pt 2), 723-728 (1996).
67. Grekin RJ. Vollmer AP, Sider RS: Pressor effects of portal venous oleate infusion. A proposed mechanism for obesity hypertension. Hypertension 26(1), 193-198 (1995).
68. Despres JP, Lemieux S, Lamarche B et al.: The insulin resistance - dyslipidemic syndrome: contribution of visceral obesity and therapeutic implications. Int. J. Obes. Relat. Metab. Disord. 19(Suppl. 1), S76-S86 (1995).
69. Poirier P. Lemieux I, Mauriege P et al.: Impact of waist circumference on the relationship between blood pressure and insulin: the Quebec Health Survey. Hypertension 45(3), 363-367 (2005).
70. Faria AN, Ribeiro Filho FF, Gouvela Ferreira SR, Zanella MT: Impact of visceral fat on blood pressure and insulin sensitivity in hypertensive obese women. Obes. Res. 10(12), 1203-1206 (2002).
71. Sironi AM, Gastaldelli A, Mari A et al.: Visceral fat in hypertension: influence on insulin resistance and β-Cell function. Hypertension 44(2), 127-133 (2004).
72. Thomas GN, Critchley JA, Tomlinson B et al.: Obesity, independent of insulin resistance, is a major determinant of blood pressure in normoglycemic Hong Kong Chinese. Metabolism 49(12), 1523-1528 (2000).
73. Despres JP, Nadeau A, Tremblay A et al.: Role of deep abdominal fat in the association between regional adipose tissue distribution and glucose tolerance in obese women. Diabetes 38(3), 304-309 (1989).
74. Nishina M, Kikuchi T, Yamazaki H et al.: Relationship among systolic blood pressure, serum insulin and leptin, and visceral fat accumulation in obese children. Hypertens. Res. 26(4), 281-288 (2003).
75. Van Pelt RE, Evans EM, Schechtman KB, Ehsani AA, Kohrt WM: Contributions of total and regional fat mass to risk for cardiovascular disease in older women. Am. J. Physiol. Endocrinol. Metab. 282(5), E1023-E1028 (2002).
76. Thorne A, Lonnqvist F, Apelman J, Hellers G, Arner P: A pilot study of long-term effects of a novel obesity treatment: omentectomy in connection with adjustable gastric banding. Int. J. Obes. Relat. Metab. Disord. 26(2), 193-199 (2002).
77. Klein S, Fontana L, Young VL et al.: Absence of an effect of liposuction on insulin action and risk factors for coronary heart disease. N. Engl. J. Med. 350(25), 2549-2557 (2004).
78. Giese SY, Bulan EJ, Commons GW, Spear SL, Yanovski JA: Improvements in cardiovascular risk profile with large-volume liposuction: a pilot study, Plast. Reconstr. Surg. 108(2), 510-519; discussion 520-521 (2001).
79. Gonzalez-Ortiz M, Robles-Cervantes JA, Cardenas-Camarena L, Bustos-Saldana R, Martinez-Abundis E: The effects of surgically removing subcutaneous fat on the metabolic profile and insulin sensitivity in obese women after large-volume liposuction treatment. Horm. Metab. Res. 34(8), 446-449 (2002).
80. Hayashi T, Boyko EJ, Leonetti DL et al.: Visceral adiposity and the prevalence of hypertension in Japanese Americans. Circulation 108(14), 1718-1723 (2003).
81. Shen W, Punyanitya M, Chen J et al.: Waist circumference correlates with metabolic syndrome indicators better than percentage fat. Obesity (Silver Spring) 14(4), 727-736 (2006).
82. Ferrannini E: Insulin and blood pressure: connected on a circumference? Hypertension 45(3), 347-348 (2005).
83. Ferrannini E, Iozzo P: Is insulin resistance atherogenic? A review of the evidence. Atheroscler. Suppl. 7(4), 5-10 (2006).
84. Facchini FS, Stoohs RA, Reaven GM: Enhanced sympathetic nervous system activity. The linchpin between insulin resistance, hyperinsulinemia, and heart rate. Am. J. Hypertens. 9(10 Pt 1), 1013-1037 (1996).
85. Ward KD, Sparrow D, Landsberg L et al.: Influence of insulin, sympathetic nervous system activity, and obesity on blood pressure: the Normative Aging Study. J. Hypertens. 14(3), 301-308 (1996).
86. DeFronzo RA, Goldberg M, Agus ZS: The effects of glucose and insulin on renal electrolyte transport. J. Clin. Invest. 58(1), 83-90 (1976).
87. Sechi LA, Griffin CA, Giacchetti G et al.: Abnormalities of insulin receptors in spontaneously hypertensive rats. Hypertension 27(4), 955-961 (1996).
88. Quinones Galvan A, Natali A, Baldi S et al.: Effect of insulin on uric acid excretion in humans. Am. J. Physiol. 268(1 Pt 1), E1-E5 (1995).
89. Vincent MA, Dawson D, Clark AD et al.: Skeletal muscle microvascular recruitment by physiological hyperinsulinemia precedes increases in total blood flow. Diabetes 51(1), 42-48 (2002).
90. Laine H, Knuuti MJ, Ruotsalainen U et al.: Preserved relative dispersion but blunted stimulation of mean flow, absolute dispersion, and blood volume by insulin in skeletal muscle of patients with essential hypertension. Circulation 97(21), 2146-2153 (1998).
91. Fossum E, Hoieggen A, Moan A et al.: Relationship between insulin sensitivity and maximal forearm blood flow in young men. Hypertension 32(5), 838-843 (1998).
92. Kohlman O Jr, Neves Fde A, Ginoza M et al.: Role of bradykinin in insulin sensitivity and blood pressure regulation during hyperinsulinemia. Hypertension 25(5), 1003-1007 (1995).